Second and third TNF inhibitors in European patients with axial spondyloarthritis

Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Second and third TNF inhibitors in European patients with axial spondyloarthritis : Effectiveness and impact of the reason for switching. / Linde, Louise; Ørnbjerg, Lykke Midtbøll; Brahe, Cecilie Heegaard; Wallman, Johan Karlsson; Di Giuseppe, Daniela; Závada, Jakub; Castrejon, Isabel; Díaz-Gonzalez, Federico; Rotar, Ziga; Tomšič, Matija; Glintborg, Bente; Gudbjornsson, Bjorn; Geirsson, Arni Jon; Michelsen, Brigitte; Kristianslund, Eirik Klami; Santos, Maria José; Barcelos, Anabela; Nordström, Dan; Eklund, Kari K; Ciurea, Adrian; Nissen, Michael; Akar, Servet; Hyldstrup, Lise Hejl; Krogh, Niels Steen; Hetland, Merete Lund; Østergaard, Mikkel.

I: Rheumatology (Oxford, England), 2024.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Linde, L, Ørnbjerg, LM, Brahe, CH, Wallman, JK, Di Giuseppe, D, Závada, J, Castrejon, I, Díaz-Gonzalez, F, Rotar, Z, Tomšič, M, Glintborg, B, Gudbjornsson, B, Geirsson, AJ, Michelsen, B, Kristianslund, EK, Santos, MJ, Barcelos, A, Nordström, D, Eklund, KK, Ciurea, A, Nissen, M, Akar, S, Hyldstrup, LH, Krogh, NS, Hetland, ML & Østergaard, M 2024, 'Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching', Rheumatology (Oxford, England). https://doi.org/10.1093/rheumatology/kead494

APA

Linde, L., Ørnbjerg, L. M., Brahe, C. H., Wallman, J. K., Di Giuseppe, D., Závada, J., Castrejon, I., Díaz-Gonzalez, F., Rotar, Z., Tomšič, M., Glintborg, B., Gudbjornsson, B., Geirsson, A. J., Michelsen, B., Kristianslund, E. K., Santos, M. J., Barcelos, A., Nordström, D., Eklund, K. K., ... Østergaard, M. (2024). Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching. Rheumatology (Oxford, England). https://doi.org/10.1093/rheumatology/kead494

Vancouver

Linde L, Ørnbjerg LM, Brahe CH, Wallman JK, Di Giuseppe D, Závada J o.a. Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching. Rheumatology (Oxford, England). 2024. https://doi.org/10.1093/rheumatology/kead494

Author

Linde, Louise ; Ørnbjerg, Lykke Midtbøll ; Brahe, Cecilie Heegaard ; Wallman, Johan Karlsson ; Di Giuseppe, Daniela ; Závada, Jakub ; Castrejon, Isabel ; Díaz-Gonzalez, Federico ; Rotar, Ziga ; Tomšič, Matija ; Glintborg, Bente ; Gudbjornsson, Bjorn ; Geirsson, Arni Jon ; Michelsen, Brigitte ; Kristianslund, Eirik Klami ; Santos, Maria José ; Barcelos, Anabela ; Nordström, Dan ; Eklund, Kari K ; Ciurea, Adrian ; Nissen, Michael ; Akar, Servet ; Hyldstrup, Lise Hejl ; Krogh, Niels Steen ; Hetland, Merete Lund ; Østergaard, Mikkel. / Second and third TNF inhibitors in European patients with axial spondyloarthritis : Effectiveness and impact of the reason for switching. I: Rheumatology (Oxford, England). 2024.

Bibtex

@article{ec4d1cfb6e3149c0a4f949a4da1f8f0f,

title = "Second and third TNF inhibitors in European patients with axial spondyloarthritis: Effectiveness and impact of the reason for switching",

abstract = "OBJECTIVE: To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with 1) treatment line (second and third TNFi-series) and 2) reason for withdrawal from the preceding TNFi (lack of efficacy (LOE) versus adverse events (AE)).METHODS: Prospectively collected routine care data from 12 European registries were pooled. Rates for 12-month drug retention and 6-month remission (Ankylosing Spondylitis Disease Activity Score C-reactive protein inactive disease (ASDAS-ID)) were assessed in second and third TNFi-series and stratified by withdrawal reason.RESULTS: We included 8254 s and 2939 third TNFi-series; 12-month drug retention rates were similar (71%). Six-month ASDAS-ID rates were higher for the second (23%) than third TNFi (16%). Twelve-month drug retention rates for patients withdrawing from the preceding TNFi due to AE versus LOE were similar for the second (68% and 67%) and third TNFi (both 68%), while for the second TNFi, rates were lower in primary than secondary non-responders (LOE < 26 versus ≥26 weeks) (58% versus 71%, p< 0.001). Six-month ASDAS-ID rates for the second TNFi were higher if the withdrawal reason was AE (27%) versus LOE (17%), p< 0.001, while similar for the third TNFi (19% versus 13%, p= 0.20).CONCLUSION: A similar proportion of axSpA patients remained on a second and third TNFi after one year, but with low remission rates for the third TNFi. Remission rates on the second TNFi (but not the third) were higher if the withdrawal reason from the preceding TNFi was AE versus LOE.",

author = "Louise Linde and {\O}rnbjerg, {Lykke Midtb{\o}ll} and Brahe, {Cecilie Heegaard} and Wallman, {Johan Karlsson} and {Di Giuseppe}, Daniela and Jakub Z{\'a}vada and Isabel Castrejon and Federico D{\'i}az-Gonzalez and Ziga Rotar and Matija Tom{\v s}i{\v c} and Bente Glintborg and Bjorn Gudbjornsson and Geirsson, {Arni Jon} and Brigitte Michelsen and Kristianslund, {Eirik Klami} and Santos, {Maria Jos{\'e}} and Anabela Barcelos and Dan Nordstr{\"o}m and Eklund, {Kari K} and Adrian Ciurea and Michael Nissen and Servet Akar and Hyldstrup, {Lise Hejl} and Krogh, {Niels Steen} and Hetland, {Merete Lund} and Mikkel {\O}stergaard",

note = "{\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.",

year = "2024",

doi = "10.1093/rheumatology/kead494",

language = "English",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

}

RIS

TY - JOUR

T1 - Second and third TNF inhibitors in European patients with axial spondyloarthritis

T2 - Effectiveness and impact of the reason for switching

AU - Linde, Louise

AU - Ørnbjerg, Lykke Midtbøll

AU - Brahe, Cecilie Heegaard

AU - Wallman, Johan Karlsson

AU - Di Giuseppe, Daniela

AU - Závada, Jakub

AU - Castrejon, Isabel

AU - Díaz-Gonzalez, Federico

AU - Rotar, Ziga

AU - Tomšič, Matija

AU - Glintborg, Bente

AU - Gudbjornsson, Bjorn

AU - Geirsson, Arni Jon

AU - Michelsen, Brigitte

AU - Kristianslund, Eirik Klami

AU - Santos, Maria José

AU - Barcelos, Anabela

AU - Nordström, Dan

AU - Eklund, Kari K

AU - Ciurea, Adrian

AU - Nissen, Michael

AU - Akar, Servet

AU - Hyldstrup, Lise Hejl

AU - Krogh, Niels Steen

AU - Hetland, Merete Lund

AU - Østergaard, Mikkel

PY - 2024

Y1 - 2024

N2 - OBJECTIVE: To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with 1) treatment line (second and third TNFi-series) and 2) reason for withdrawal from the preceding TNFi (lack of efficacy (LOE) versus adverse events (AE)).METHODS: Prospectively collected routine care data from 12 European registries were pooled. Rates for 12-month drug retention and 6-month remission (Ankylosing Spondylitis Disease Activity Score C-reactive protein inactive disease (ASDAS-ID)) were assessed in second and third TNFi-series and stratified by withdrawal reason.RESULTS: We included 8254 s and 2939 third TNFi-series; 12-month drug retention rates were similar (71%). Six-month ASDAS-ID rates were higher for the second (23%) than third TNFi (16%). Twelve-month drug retention rates for patients withdrawing from the preceding TNFi due to AE versus LOE were similar for the second (68% and 67%) and third TNFi (both 68%), while for the second TNFi, rates were lower in primary than secondary non-responders (LOE < 26 versus ≥26 weeks) (58% versus 71%, p< 0.001). Six-month ASDAS-ID rates for the second TNFi were higher if the withdrawal reason was AE (27%) versus LOE (17%), p< 0.001, while similar for the third TNFi (19% versus 13%, p= 0.20).CONCLUSION: A similar proportion of axSpA patients remained on a second and third TNFi after one year, but with low remission rates for the third TNFi. Remission rates on the second TNFi (but not the third) were higher if the withdrawal reason from the preceding TNFi was AE versus LOE.

AB - OBJECTIVE: To investigate real-world effectiveness of tumor necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) and the association with 1) treatment line (second and third TNFi-series) and 2) reason for withdrawal from the preceding TNFi (lack of efficacy (LOE) versus adverse events (AE)).METHODS: Prospectively collected routine care data from 12 European registries were pooled. Rates for 12-month drug retention and 6-month remission (Ankylosing Spondylitis Disease Activity Score C-reactive protein inactive disease (ASDAS-ID)) were assessed in second and third TNFi-series and stratified by withdrawal reason.RESULTS: We included 8254 s and 2939 third TNFi-series; 12-month drug retention rates were similar (71%). Six-month ASDAS-ID rates were higher for the second (23%) than third TNFi (16%). Twelve-month drug retention rates for patients withdrawing from the preceding TNFi due to AE versus LOE were similar for the second (68% and 67%) and third TNFi (both 68%), while for the second TNFi, rates were lower in primary than secondary non-responders (LOE < 26 versus ≥26 weeks) (58% versus 71%, p< 0.001). Six-month ASDAS-ID rates for the second TNFi were higher if the withdrawal reason was AE (27%) versus LOE (17%), p< 0.001, while similar for the third TNFi (19% versus 13%, p= 0.20).CONCLUSION: A similar proportion of axSpA patients remained on a second and third TNFi after one year, but with low remission rates for the third TNFi. Remission rates on the second TNFi (but not the third) were higher if the withdrawal reason from the preceding TNFi was AE versus LOE.

U2 - 10.1093/rheumatology/kead494

DO - 10.1093/rheumatology/kead494

M3 - Journal article

C2 - 37738257

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

ER -

ID: 387337999

Biomedicinsk Institut